Will Regentis Biomaterials stock go up?

According to Danelfin AI, Regentis Biomaterials has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (32.07%) is -18.75% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Regentis Biomaterials stock?

The Regentis Biomaterials target price is $4.04 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Regentis Biomaterials stock right now?

Regentis Biomaterials has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (32.07%) is -18.75% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Regentis Biomaterials stock is a good buy .

Is Regentis Biomaterials undervalued right now?

Based on analysts, the average price target downside for Regentis Biomaterials is 0.00% (1Y). According to Danelfin AI, Regentis Biomaterials has today an AI Score of 1/10 (Strong Sell Rating).

What was the price range of Regentis Biomaterials stock over the past 12 months?

The Regentis Biomaterials stock price range over the past 12 months has been - - -.

What is going on with Regentis Biomaterials stock in the last 3 months?

The Regentis Biomaterials stock performance in the last quarter has been +34.66%.

Does Regentis Biomaterials offer dividend payments?

No, Regentis Biomaterials does not currently pay dividends.

What is the current market capitalization of Regentis Biomaterials?

Regentis Biomaterials's market cap is $20.87M, as of 2026-07-03 08:00.

REGENTIS BIOMATERIALS LTD/IS (RGNT) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

RGNT AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Sentiment-7.08%
How analysts and the market view the stock
Momentum-4.99%
Direction and strength of recent price movements
Volatility-3.37%
How much the stock price tends to fluctuate
Valuation-2.69%
How the stock is priced relative to its fundamentals
Size & Liquidity-0.35%
Company size and trading liquidity
Growth-0.28%
Expected pace of revenue and earnings expansion

RGNT probability advantage of beating the market (3M):

-18.75%

AI Score

Strong Sell

Regentis Biomaterials (RGNT) has an AI Score of 1/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -18.75% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of RGNT (32.07%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
RGNT probability advantage of beating the market (3M)-18.75%
RGNT probability of beating the market (3M)32.07%

RGNT probability advantage of beating the market (3M): -18.75%

The AI-powered overall analysis of Regentis Biomaterials (RGNT) is based on the 22 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of RGNT:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Sentiment Impact (Long Tail)	-	N/A	-4.64%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-2.47%
Technical	Technicals Impact (Long Tail)	-	N/A	-2.07%
Technical	Maximum Volatility	14.19%		-1.99%
Sentiment	Industry (GICS)	Medical Instruments & Supplies	N/A	-0.88%
Technical	Chart Pattern (90d)	figure_83	N/A	-0.86%
Technical	Chart Pattern (120d)	figure_63	N/A	-0.83%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.75%
Technical	Distance from KAMA (20d)	0.16%		-0.68%
Technical	Normalized Average True Range (50d)	18.73%		-0.63%
Technical	Upgrade to unlock			-0.60%
Sentiment	Upgrade to unlock			-0.54%
Technical	Upgrade to unlock			+0.50%
Technical	Upgrade to unlock			-0.45%
Technical	Upgrade to unlock			-0.45%

Rest of Alpha Signals: -1.42%

RGNT probability advantage of beating the market (3M)Total:-18.75%
RGNT AI Score

Significant changes Vs previous day

RGNT Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$4.04
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

RGNT Proven Sell Signal & Price Forecast

This is the price chart for RGNT from January 3, 2026 until today. The chart indicates, in red, the 0 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

RGNT Average Past Performance & Loss Rate

Three months after its 118 Sell signals since July 2026, RGNT had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

118 Past RGNT Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				0.00%
Average Alpha				0.00%
Loss Rate (% Negative Perf.)				100.00%
% Negative Alpha				100.00%

RGNT Frequently Asked Questions

Will Regentis Biomaterials stock go up?
According to Danelfin AI, Regentis Biomaterials has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (32.07%) is -18.75% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Regentis Biomaterials stock?
Is it a good time to buy, sell, or hold Regentis Biomaterials stock right now?
Is Regentis Biomaterials undervalued right now?
What was the price range of Regentis Biomaterials stock over the past 12 months?
What is going on with Regentis Biomaterials stock in the last 3 months?
Does Regentis Biomaterials offer dividend payments?
What is the current market capitalization of Regentis Biomaterials?

REGENTIS BIOMATERIALS LTD/IS Company Profile

REGENTIS BIOMATERIALS LTD/IS (RGNT) develops and commercializes advanced biomaterials for the medical device industry. The company focuses on creating innovative solutions that support tissue repair and regeneration within the human body, addressing unmet needs in various medical fields. It primarily serves medical device manufacturers, pharmaceutical companies, and healthcare providers seeking biocompatible and functional biological materials for their products and procedures.

The company's core expertise centers on its proprietary hydrogel technology platform, known for its unique biological and mechanical properties. These advanced hydrogels are engineered to closely mimic the structural and mechanical characteristics of natural human tissues, providing an optimal scaffold for cellular activity and tissue integration. They are designed to integrate effectively with the body's biological processes, facilitating cellular growth, promoting healing, and providing essential structural support during recovery. This versatile technology forms the foundation for a range of medical applications, offering adaptable solutions for complex clinical challenges in regenerative medicine and beyond.

REGENTIS BIOMATERIALS LTD/IS applies its hydrogel platform across several key therapeutic areas. In orthopedics, it develops specialized materials for cartilage repair, addressing joint damage and promoting the natural restoration of articular tissue function and mobility. The company also creates products for soft tissue reconstruction, aiding in the repair of ligaments, tendons, and other connective tissues following injury or disease. Furthermore, its technology explores applications in wound management, ophthalmology, and aesthetic medicine, providing diverse and adaptable solutions for patient care. These biomaterials are designed to be biodegradable, allowing for gradual absorption and replacement by native tissue as the body heals and restores its natural structure.

The company's offerings are utilized by medical device companies, hospitals, and specialized clinics across various global markets. Its revenue is generated through the sale of its biomaterial products and through strategic licensing agreements for its proprietary hydrogel technology. REGENTIS BIOMATERIALS LTD/IS reaches its global customer base through a combination of direct sales efforts and collaborations with distribution partners.

Sector:Healthcare
Country:-
Industry:
Address:-
Employees:-
Website:-

Pros

High switching costs for established medical implants

Intellectual property protection for biomaterial formulations

Favorable demographic trends from an aging global population

Rigorous regulatory approval processes for medical devices

Specialized manufacturing processes for medical-grade materials

Cons

Exposure to changes in healthcare reimbursement policies

Dependency on lengthy and costly clinical trial outcomes

Risk of material science technological obsolescence

Potential for product liability litigation in medical applications

Revenue concentration within specific therapeutic areas

	Company	AI Score	Compare
1	SRTAStrata Critical Medical Inc
2	AEONAEON Biopharma Inc
3	GLAS
4	TLXTELIX PHARMACEUTICALS LTD
5	OPTHOptimi Health Corp
6	SLBT
7	RGNTREGENTIS BIOMATERIALS LTD/IS

	Company	AI Score	Compare
1	SRTAStrata Critical Medical Inc
2	AEONAEON Biopharma Inc
3	GLAS
4	TLXTELIX PHARMACEUTICALS LTD
5	OPTHOptimi Health Corp
6	SLBT
7	RGNTREGENTIS BIOMATERIALS LTD/IS

RGNT Stock AI Analysis High Risk